
Resource Vault
Explore our Resource Vault for insightful documents and materials to enhance your understanding and journey with Cyagen.
All
Brochure
Pamphlet
Poster
Trends & Analysis
White Paper
Milestones & Highlights
Filter By

Engineering an isogenic APP Swedish human iPSC-derived cortical neuron model of Familial Alzheimer’s disease that recapitulates hallmark amyloid and tau pathologies
Describing an isogenic human iPSC-derived cortical neuron model of familial Alzheimer’s disease, created by introducing the APP Swedish (K670N/M671L) mutation into healthy-donor PBMC-derived iPSCs, with matched parental WT controls and validated amyloid and phospho-tau phenotypes.
Poster

HUmanized Genomic Ortholog (HUGO™) mouse models enable preclinical evaluation of human-targeted siRNA and antisense oligonucleotide therapies
Introducing the HUGO™ (HUmanized Genomic Ortholog) platform, which uses TurboKnockout™ technology to swap up to 500 kb of mouse genomic sequence for the human ortholog — promoters, exons, introns, and UTRs intact — and validates two such models with an approved siRNA and a splice-modulating ASO.
Poster

Humanized TFRC and CD98hc mouse models for BBB and AAV brain delivery
An integrated BBB shuttle development workflow combining humanized TFRC and CD98hc mouse models with the HUGO-Nano™ fully human VHH discovery platform, demonstrating receptor-dependent antibody brain delivery in vivo and identifying anti-hTfR1 and anti-CD98hc nanobody candidates for CNS delivery of antibodies and AAV.
Poster

Next-generation humanized NKG mouse platforms enable pharmacodynamic and antitumor evaluation of in vivo CAR therapies
Evaluating two complementary humanized NKG mouse platforms for preclinical testing of in vivo CAR therapies. huHSC-NKG-ProF mice supported longitudinal pharmacodynamic assessment of CD19-targeting CAR-mediated B-cell depletion, while T-cell-rich huPBMC-NKG mice enabled rapid antitumor evaluation of LNP-delivered BCMA-targeting CAR in a multiple myeloma xenograft model.
Poster

AI-engineered AAV Capsid Enables Intravitreal Delivery for the Treatment of Diverse Retinal Degenerations
AI-guided, iterative design–screen–validate capsid engineering (NGS-trained viability and retina-targeting models), followed by in vitro assays (HEK293T transduction, serum transduction-inhibition, heparin competition) and in vivo validation in mouse and cynomolgus monkey models via intravitreal delivery.
Poster

SITC 2026: Immune Mechanisms, Core Targets & Emerging Therapies
This report analyzes the 41st SITC Annual Meeting (2026), covering 1,065 regular abstracts, 42 award abstracts and 19 late-breaking abstracts. Key signals include tumor-localized conditional activation, costimulation-enhanced T-cell engagers, the PD-1×VEGF bispecific race, in vivo cell engineering and biparatopic ADCs, with competitive hotspots across PD-1/PD-L1, CD3, VEGF, GPC3, STEAP2, PSMA, KRAS and IL-12.
Trends & Analysis
Load More



